Clinical Trials Logo
  1. Home
  2. Amyloid Cardiomyopathy
  3. NCT05103943

Amyloidosis TTR Flow Reserve Evaluation — AMYTRE  

Amyloid Cardiomyopathy Clinical Trial

Official title:
Amyloidosis TTR Flow Reserve Evaluation

Clinical Trial Summary

Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis (TTR) without obstructive epicardial coronary artery disease (CAD). It was found that coronary microvascular dysfunction was highly prevalent in subjects with cardiac amyloidosis, even in the absence of epicardial CAD. The investigators found lower stress and rest myocardial blood flow (MBF) and lower myocardial flow reserve (MFR) in their cardiac PET (Positron emission tomography) study (13N), including 21 patients. The advances in SPECT technology including cadmium zinc telluride (CZT) detectors allow to evaluate the MBF and MFR estimation by SPECT as shown in both experimental animal models and also in clinical studies with comparison to PET. SPECT is more widely available than cardiac PET. Thus, the investigators would like: 1. to confirm the results of Dorbala et al using SPECT, and 2. to go further with evaluation of the effect of Tafamidis on microvascular dysfunction.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05103943
Study type Interventional
Source Centre Hospitalier Régional d'Orléans
Contact Aurélie DESPUJOLS
Phone +33238744071
Email aurelie.despujols@chr-orleans.fr
Status Recruiting
Phase N/A
Start date February 24, 2022
Completion date February 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05699044 - Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation
Active, not recruiting NCT04738266 - Unmasking the Prevalence of AC in an Unselected Echocardiographic Population
Recruiting NCT05797857 - Exercise Training in Transthyretin Cardiac Amyloidosis N/A
Completed NCT03860935 - Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Phase 3
Recruiting NCT03397810 - Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study N/A
Recruiting NCT05795400 - Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy N/A
Recruiting NCT06048601 - 18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis N/A
Recruiting NCT06328075 - Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT04776824 - Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Recruiting NCT06261216 - Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
Active, not recruiting NCT03431896 - Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Active, not recruiting NCT03536767 - Open-Label Study of AG10 in Patients With Cardiomyopathy Phase 2
Active, not recruiting NCT05452850 - Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
Active, not recruiting NCT05448716 - Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy